Researchers constructed family trees with up to 13 million members from public genealogy profiles, but some disagree with their conclusions on the genetics of longevity.
American customers' interest in their genetic ancestry continues to be the primary driver of the consumer genomics market and shows no signs of diminishing.
With the rollout of Insitome's first app, consumers have the chance to explore their heritage in a new context that could reshape the ancestry testing market.
The company has developed a suite of initial products focused on ancestry that will compete with offerings from 23andMe, AncestryDNA, and Family Tree DNA.
Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.
